A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects

NCT04056130 | Completed Phase 1 DMC

• 1 other identifier: KBL-CURE-2019-01
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

The study is designed to investigate the safety and tolerability of KBL697 in healthy volunteers. KBL697 has been developed as a potential new treatment for atopic dermatitis (AD).

Conditions

Atopic Dermatitis (AD)

Outcome Measures

Primary Outcomes (6)

• Safety and tolerability measure through Adverse Events/Serious Adverse Events

  Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

  Measurements at Baseline till 28 days

• Safety and tolerability measure through Vital Sign

  Measured by result of the Vital Sign(blood pressure, heart rate, axillary body temperature, respiratory rate)

  Measurement at Baseline till 28 days

• Safety and tolerability measure through 12-lead ECG

  Measured by result of the ECG measurements and findings

  Measurement at Baseline till 28 days

• Safety and tolerability measure through Physical exam

  Measured by result of the physical exam which includes general appearance, skin, eyes/ears/nose/throat, head and neck, cardiovascular, respiratory, abdomen, extremities, lymph nodes, musculoskeletal and neurologic

  Measurement at Baseline till 28 days

• Safety and tolerability measure through Routine Stool Examination

  Measured by result of the Bristol Stool Examination, Occult blood, Parasites

  Measurement at Baseline till 28 days

• Safety and tolerability measure through Clinical laboratory results

  Measured by clinically significant change from baseline clinical laboratory results

  Measurement at Baseline till 28 days

Other Outcomes (1)

• Difference in the change from baseline in profile of faecal KBL697 between treatment arms

  Measurements at Baseline till 28 days

Study Arms (4)

Cohort SAD1

EXPERIMENTAL

9 Subjects for SAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.

Drug: KBL697

Cohort SAD2

EXPERIMENTAL

9 Subjects for SAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo.

Drug: KBL697

Cohort MAD1

EXPERIMENTAL

9 Subjects for MAD 1 Cohort. 6 subjects on KBL697, 3 subjects on Placebo

Drug: KBL697

Cohort MAD2

EXPERIMENTAL

9 Subjects for MAD 2 Cohort. 6 subjects on KBL697, 3 subjects on Placebo

Drug: KBL697

Interventions

KBL697 DRUG

Part A: 1 day 460mg/day of KBL697 or placebo Route of Administration: Oral

Also known as: Placebo

Cohort SAD1

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects able to read and understand, and willing to sign the informed consent form (ICF)
• Male or female, aged 18 to 60 years (inclusive) at the time of Screening
• Body mass index (BMI) of 18 kg/m2 to ≤ 30 kg/m2 (both inclusive)
• Willing and able to comply with clinic visits (including confinement to clinical trial unit) and study-related procedures
• No history of allergic asthma
• Baseline laboratory test values within reference ranges based on the blood and urine samples taken at screening and on Day -1. Out of normal ranges values may be accepted by the Investigator, if not clinically significant.
• Male subjects must abstain from heterosexual activities or agree to use a condom from screening through 90 days after the final dose of study drug. Women of child-bearing potential (WOCBP) must also abstain from heterosexual activities or agree to use effective contraception from screening through 90 days after the final dose of study drug.
• Ability to remain in the study centre for up to a 3-day period for Part A of the study and up to a 15-day period for Part B of the study.
• The subject is, in the opinion of the Investigator, generally healthy based on assessment of medical history, physical examination, vital signs, electrocardiogram (ECG), and the results of the haematology, clinical chemistry, urinalysis, serology, and other relevant laboratory tests.
• Subject willing to allow storage of samples for genetic make-up in future studies.

You may not qualify if:

• Female participants who are pregnant or lactating
• The participant's corrected QT interval (QTcF) (Fridericia's correction) is \>450 msec (males), and \>470 msec (females) at Screening or on Day -1. An out-of-range or abnormal ECG will be repeated at PI's discretion. In total, 3 ECGs should be recorded consecutively at Screening and on Day -1, and the PI (or delegate) must evaluate the triplicate ECG. If the participant's QTcF is \>450 msec (males) or \>470 msec (females) on at least 2 ECGs or have structural cardiac abnormalities, the participant must be excluded
• The participant has taken prescription (including antibiotics) or non-prescription medication, herbal remedies, vitamins or minerals, any probiotic drinks and yeast supplements (e.g. Mutaflor®, Bioflor®) within 14 days prior to the first dose of study product unless in the opinion of the PI the medication will not compromise participant safety or interfere with study procedures or data validity. Participant may be rescreened after a washout period of 14 days. Please note use of oral contraceptives and paracetamol up to 2 g/day and/or nonsteroidal anti-inflammatory drugs for symptomatic relief of minor symptoms are allowed
• Participant has functional GI disorders
• Participant is a current smoker or has used nicotine containing products within 6 months prior to Screening visit
• The participant has a substance abuse-related disorder or has a history of drug, alcohol and/or substance abuse deemed significant by the PI
• The participant has taken any IP within 30 days prior to the first dose of study product or 5 half-lives, whichever is longer
• The participant has a history of significant hypersensitivity or anaphylaxis involving any drug (including ampicillin, clindamycin or imipenem), any constituent of the IP, food or other precipitating agent (e.g. bee sting). Please note participants with clinically stable mild allergic conditions such as hay fever and mild eczema may be enrolled at the discretion of the PI
• Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HbsAg), or hepatitis C virus antibody (anti-HCV)at Screening visit.
• Positive screen for drugs of abuse and cotinine at Screening or on Day -1. Positive screen for alcohol on Day -1.
• The participant is, in the opinion of the PI, unlikely to comply with the clinical study protocol or is unsuitable for any other reason.

Sponsors & Collaborators

• KoBioLabs: lead
• Novotech (Australia) Pty Limited: collaborator

Study Sites (1)

Nucleus Network

Melbourne, Victoria, 3004, Australia

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Ben Snyder, Dr

  Nucleus Network

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2019
• First Posted: August 14, 2019
• Study Start: October 4, 2019
• Primary Completion: December 23, 2019
• Study Completion: January 7, 2020
• Last Updated: September 8, 2021

Record last verified: 2021-09

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)